Trevi Therapeutics, Inc. Common Stock (TRVI) is a publicly traded Healthcare sector company. As of September 17, 2026, TRVI trades at $15.20 with a market cap of $2.14B and a P/E ratio of -32.10. TRVI moved +1.33% today. Year to date, TRVI is +27.92%; over the trailing twelve months it is +90.60%. Its 52-week range spans $3.77 to $20.22. Analyst consensus is strong buy with an average price target of $29.00. Rallies surfaces TRVI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
10 analysts cover TRVI: 0 strong buy, 10 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $29.00.
| Metric | Value |
|---|---|
| Price | $15.20 |
| Market Cap | $2.14B |
| P/E Ratio | -32.10 |
| EPS | $-0.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.22 |
| 52-Week Low | $3.77 |
| Volume | 1.12M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-47.91M |
| Gross Margin | 0.00% |
10 analysts cover TRVI: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.00.